



ISLAMIC REPUBLIC OF IRAN

MINISTRY OF HEALTH AND MEDICAL EDUCATION

Ref: 665/92964

Date: 9/2/2024

Attach: No

CERTIFICATE of PHARMACEUTICAL PRODUCT

This certificate conforms to the format recommended by the World Health Organization.

Exporting / Certifying country:

Islamic Republic of Iran

Importing / Requesting country:

Azerbaijan

1.1. Name and dosage form of the product:

Paclinab 100 mg (Paclitaxel albumin-bound particles)
Lyophilized powder for suspension for infusion

1.2. Active ingredient(s) and amount(s) per unit dose:

Paclitaxel 100 mg

1.3. Excipient(s) and amount(s) per unit dose:

Human serum albumin solution (4744.80 mg), Acetone (1500 mg), Water for injection-WFI (16567 mg)
[Sodium hydroxide, Hydrochloric acid: for pH adjustment]

1.4. Is this product licensed to be placed on the market for use in the exporting country?

Yes No

1.5. Is this product actually on the market in the exporting country?

Yes No

2.A.1. Number of product license and date of issue:

The registration number is: 1706300113695039.

The number of product license is: 5922596448887503 and the date of issue is: 11/05/2023.

2.A.2. Product license holder (name and address):

Nano Daru Pajuhan Pardis

No. 18, Between Motahari St. & South Etaati St., Marzadaran Blvd., Tehran, Iran.

Tel: +98 (21) 58107

Fax: +98 (21) 8611 1563

Email: Info@nanodaru.com

Manufacturing Site: Behnood Pharmed Incubation Center, No. 110, Bahman St., Karafarinan Blvd.,
Sepehr Industrial Zone, Nazarabad City, Alborz Province, Iran.





ISLAMIC REPUBLIC OF IRAN
MINISTRY OF HEALTH AND MEDICAL EDUCATION

Ref: 665/92964
Date: 9/2/2024
Attach: No

2.A.3. Status of product license holder:

a b c

2.A.4. Is a summary basis for approval appended?

Yes No

2.A.5. Is the attached, officially approved product information complete and consistent with the license?

Yes No Not provided

3.1. Does the certifying authority arrange for periodic inspection of the manufacturing plant in which the dosage form is produced?

Yes No Not provided

3.2. Periodicity of routine inspections (years):

At an appropriate frequency based on risk

3.3. Has the manufacture of this type of dosage form been inspected?

Yes No

3.4. Do the facilities and operations conform to the GMP as recommended by the World Health Organization?

Yes No

4.1. Does the information submitted by the applicant satisfy the certifying authority on all aspects of the manufacture of the product?

Yes No

Address of the certifying authority:

Division of Pharmaceutical and Narcotic Affairs of Ministry of Health
Food and Drug Adm.

M O H

FDA Central Bldg., No. 30, Fakhr Razi St., Enghelab Ave., Tehran, Iran

Postal Code: 1314715311

Tel: (+98)-21-61927000

Fax: (+98)-21-66405571

Dr. Mohammad Peikanpour
IFDA Director General for
Drugs and Controlled Materials

